BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We hosted the management of Sun Pharmaceutical Industries Ltd., to gain insights into the current business outlook. Scaling up of the global Specialty portfolio would remain the key focus area with Ilumya, Winlevi and Cequa being the main growth drivers.
In India, the target would be to grow in line faster than the market on the back of new addition of medical representatives and new launches. The recent MR addition was mainly to enhance focus on specialist doctors in tier II and beyond cities.
Sun Pharma's management sees scope for outperformance in domestic market with the help of geographical expansion. The management has reiterated its single-digit revenue growth guidance for FY24. We remain positive on Sun Pharma on the back of the following catalysts:
Ramp-up of branded/specialty business in the U.S. (recently acquired Deuruxolitinib would further strengthen the specialty pipeline),
continued growth in India business,
potential inorganic opportunity due to a strong balance sheet, especially in dermatology, ophthalmology and oncology specialty segments and
maintenance of healthy Ebitda margin at ~27% despite higher research and development spends.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2024-08/15891ced-191e-4228-a1b2-a722e32776be/09.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Economic Slowdown Cloud Hangs Over Markets Rally, Says Piper Serica's Agarwal
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-03/aa5e8de2-f397-4796-9955-caa416286c33/Colourful_medicines_arranged_for_drug___Source_pxhere_.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
India Pharma - Pick-Up In Acute Therapies Supporting IPM Growth In July: Motilal Oswal
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-08-23/x7arxu1l/Aditya Khemka_Hero Image.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Investors' Focus To Shift To Value-Driven Opportunities In Healthcare Sector: InCred's Aditya Khemka
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-12/bc048476-030a-4c18-b9e3-fe9c22663596/Sun_Pharma_website.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Sun Pharma - Deuruxolitinib Approval To Strengthen Specialty Business: HDFC Securities
![timelogo](/images/amp-time.png)